3 results
Approved WMOCompleted
To assess sorafenib pharmacokinetics and biodistribution, K-Ras mutational status, tumor uptake and tumor response in NSCLC patients.
Approved WMOCompleted
The first objective is to evaluate the superiority of CHF 5259 pMDI (glycopyrrolate bromide) (50 µg total daily dose) versus placebo in terms of FEV1 AUC0-12h normalised by time on Day 42.Key Secondary objectiveTo evaluate the superiority of CHF…
Approved WMOCompleted
Primary Objectives:• To determine the Recommended Dose of Expanion or the MTD for MP0317 as monotherapy in patients with advanced solid tumors (dose-escalation part only)• To characterize the safety and tolerability of MP0317 as monotherapy in…